Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

Also called NCT01970033

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01970033
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01970033. Randomized; quadruple masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2014-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes
Intervention (Drug)
Placebo
Intervention (Drug)
SP2086 50 mg b.i.d.
Intervention (Drug)
SP2086 100 mg q.d.
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01970033
Content hash
6fb4bb0c2439272d52ee7619ccebcc82509d05b8143be60f9451dc017e5c62d5